Korean iPSC derived cell provider, Nexel, joins Germany Nexel signing strategic partnership with Nanion Technology located in Germany
Dec 17, 2020, 10:23
Nexel, Korean iPSC derived cell provider, announced that it has signed a strategic partnership with Nanion Technology in Germany.
With this partnership, Nexel received technical support from Nanion Technology for the development of a toxicity assessment analysis method using cardiomyocytes derived from induced pluripotent stem cells, and jointly marketed the cell products made from Nexel in international toxicology research and business fields. A reference lab was set up in the headquarters of Nexel to demonstrate Nanion Technology's analysis equipment.
In particular, with this reference lab installation, domestic research institutes, pharmaceutical companies, and bio companies wishing to evaluate toxicity using cardiomyocytes derived from induced pluripotent stem cells can directly demonstrate using Nexel’s cell products and Nanion Technology's analysis equipment. Also, based on this, it is expected to become the basis for expanding new cardiac toxicity assessment methods in the domestic toxicity assessment market.
The cardiac toxicity assessment method using Nexel's cell products and Nanion Technology's analysis equipment is based on the evaluation method of the 'New Cardiac Toxicity Assessment Guideline' currently being revised by the International Drug Regulatory and Regulatory Commission(ICH). Nanion Technology is a global company that supplies measuring equipment for the world. It is headquartered in Munich, Germany, and it has subsidiaries in the US, Japan, China and Denmark.
The CEO of Nexel said, “We are proud of the partnership between Nexel and Nanion Technology. We are one step closer to leading the market for toxicity assessment using cardiomyocytes derived from induced pluripotent stem cells, due to the synergy effect of our business through this partnership. We are happy to be able to go.”
Meanwhile, Nexel is the first provider in Korea to acquire an induced pluripotent stem cell commercialization license, and launch cell products for toxicity evaluation of new drugs. Nexel is the only one in Korea to join the International Health and Environment Science Committee(HESI) research group and the International Drug Regulation and Harmonization Committee(ICH). Nexel is participating in the revising of the 'New Cardiac Toxicity Assessment Guideline'.
For more information on Nexel, visit http://www.nexel.co.kr.
Contact : Tel. +82-2-2088-8886 / firstname.lastname@example.org
Related Link : http://www.nexel.co.kr
Written by Hanmir PRNews
► This is a news release distributed by Hanmir PR news on behalf of Nexel.
► News provided by Nexel
#nexel #cardiomyocytes derived from induced pluripotent stem cells #cell products #cardiac toxicity assessment methods #korean ipsc derived cell provider
The HANMIR Online PR News is a go-to source that
focuses on small-medium sized enterprises in South Korea.
Media Contacts +82-(0)2-6265-2100 email@example.com